Effects of the tumor microenvironment on the efficacy of tumor immunotherapy

Immunological Investigations

Volumn 35, Issue 3-4, 2006, Pages 359-394

  Neeson, Paul ^a   Paterson, Yvonne ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chemokine; Effector T cells; Interferon gamma; Lymphocyte trafficking; Signal transducer and activator of transcription (STAT); Tumor; Tumor infiltrating lymphocyte

Indexed keywords

CANCER VACCINE; GAMMA INTERFERON; STAT PROTEIN; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; CANCER IMMUNOTHERAPY; CELL DEATH; CELL KILLING; CELL MIGRATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; EFFECTOR CELL; ENDOTHELIUM CELL; GROWTH INHIBITION; IMMUNE RESPONSE; MICROENVIRONMENT; MOLECULAR MECHANICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; STROMA CELL; T LYMPHOCYTE ACTIVATION; TUMOR; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR REGRESSION; TUMOR VASCULARIZATION; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CHEMOTAXIS, LEUKOCYTE; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; NEOPLASMS; STAT1 TRANSCRIPTION FACTOR; STAT3 TRANSCRIPTION FACTOR; T-LYMPHOCYTES;

EID: 33747619590     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.1080/08820130600755009     Document Type: Review

References (193)

1. Abe, M., Kondo, T., Xu, H., Fairchild, R. L. (1996). Interferon-gamma inducible protein (IP-10) expression is mediated by CD8+ T cells and is regulated by CD4+ T cells during the elicitation of contact hypersensitivity. J Invest Dermatol 107(3):360-366.
2. Adams, J. M., Harris, A. W., Pinkert, C. A., Corcoran, L. M., Alexander, W. S., Cory, S., Palmiter, R. D., Brinster, R. L. (1985). The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature 318(6046):533-538.
3. Ansel, K. M., Cyster, J. G. (2001). Chemokines in lymphopoiesis and lymphoid organ development. Curr. Opin. Immunol. 13(2):172-179.
4. Arbeit, J. M., Munger, K., Howley, P. M., Hanahan, D. (1994). Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J. Virol. 68(7):4358-4368.
5. Armstrong, T. D., Jaffee, E. M. (2002). Cytokine modified tumor vaccines. Surg. Oncol. Clin. N. Am. 11(3):681-696.
6. Arnold, J., de Boer, E. C., O'Donnell, M. A., Bohle, A., Brandau, S. (2004). Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma. J. Immunother. 27(2):116-123.
7. Aslakson, C. J., Miller, F. R. (1992). Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res. 52(6):1399-1405.
8. Bach, E. A., Aguet, M., Schreiber, R. D. (1997). The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu. Rev. Immunol. 15:563-591.
9. Balkwill, F., Mantovani, A. (2001). Inflammation and cancer: back to Virchow? Lancet 357(9255):539-545.
10. Biragyn, A., Ruffini, P. A., Coscia, M., Harvey, L. K., Neelapu, S. S., Baskar, S., Wang, J. M., Kwak, L. W. (2004). Chemokine receptor-mediated delivery directs self-tumor antigen efficiently into the class II processing pathway in vitro and induces protective immunity in vivo. Blood 104(7):1961-1969.
11. Boehm, U., Klamp, T., Groot, M., Howard, J. C. (1997). Cellular responses to interferon-gamma. Annu. Rev. Immunol. 15:749-795.
12. Bour, H., Peyron, E., Gaucherand, M., Garrigue, J. L., Desvignes, C., Kaiserlian, D., Revillard, J. P., Nicolas, J. F. (1995). Major histocompatibility complex class Irestricted CD8+ T cells and class II-restricted CD4+ T cells, respectively, mediate and regulate contact sensitivity to dinitrofluorobenzene. Eur. J. Immunol. 25(11):3006-3010.
13. Bowman, T., Garcia, R., Turkson, J., Jove, R. (2000). STATs in oncogenesis. Oncogene 19(21):2474-2488.
14. Bratt, A., Wilson, W. J., Troyanovsky, B., Aase, K., Kessler, R., Van Meir, E. G., Holmgren, L. (2002). Angiomotin belongs to a novel protein family with conserved coiled-coil and PDZ binding domains. Gene 298(1):69-77.
15. Bratt, A., Birot, O., Sinha, I., Veitonmaki, N., Aase, K., Ernkvist, M., Holmgren, L. (2005). Angiomotin regulates endothelial cell-cell junctions and cell motility. J. Biol. Chem. 280(41):34859-34869.
16. Brigati, C., Noonan, D. M., Albini, A., Benelli, R. (2002). Tumors and inflammatory infiltrates: friends or foes? Clin. Exp. Metastasis 19(3):247-258.
17. Bromberg, J. (2002). Stat proteins and oncogenesis. J. Clin. Invest. 109(9):1139-1142.
18. Bromberg, J. F., Horvath, C. M., Wen, Z., Schreiber, R. D., Darnell, J. E., Jr. (1996). Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma. Proc. Natl. Acad. Sci. USA 93(15):7673-7678.
19. Bromberg, J. F., Wrzeszczynska, M. H., Devgan, G., Zhao, Y., Pestell, R. G., Albanese, C., Darnell, J. E., Jr. (1999). Stat3 as an oncogene. Cell 98(3):295-303.
20. Burdelya, L., Kujawski, M., Niu, G., Zhong, B., Wang, T., Zhang, S., Kortylewski, M., Shain, K., Kay, H., Djeu, J., Dalton, W., Pardoll, D., Wei, S., Yu, H. (2005). Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects. J. Immunol. 174(7):3925-3931.
21. Calvo, A., Yokoyama, Y., Smith, L. E., Ali, I., Shih, S. C., Feldman, A. L., Libutti, S. K., Sundaram, R., Green, J. E. (2002). Inhibition of the mammary carcinoma angiogenic switch in C3(1)/SV40 transgenic mice by a mutated form of human endostatin. Int. J. Cancer 101(3):224-234.
22. Campbell, M. J., Carroll, W., Kon, S., Thielemans, K., Rothbard, J. B., Levy, S., Levy, R. (1987). Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits. J. Immunol. 139(8):2825-2833.
23. Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C., Levy, R. (1989). Development of a new therapeutic approach to B cell malignancy. The induction of immunity by the host against cell surface receptor on the tumor. Int. Rev. Immunol. 4(4):251-270.
24. Campbell, M. J., Esserman, L., Byars, N. E., Allison, A. C., Levy, R. (1990). Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity. J. Immunol. 145(3):1029-1036.
25. Campbell, M. J., Esserman, L., Levy, R. (1988). Immunotherapy of established murine B cell lymphoma. Combination of idiotype immunization and cyclophosphamide. J. Immunol. 141(9):3227-3233.
26. Campoli, M., Chang, C. C., Oldford, S. A., Edgecombe, A. D., Drover, S., Ferrone, S. (2004). HLA antigen changes in malignant tumors of mammary epithelial origin: molecular mechanisms and clinical implications. Breast Dis. 20:105-125.
27. Caspar, C. B., Levy, S., Levy, R. (1997). Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 90(9):3699-3706.
28. Catlett-Falcone, R., Landowski, T. H., Oshiro, M. M., Turkson, J., Levitzki, A., Savino, R., Ciliberto, G., Moscinski, L., Fernandez-Luna, J. L., Nunez, G., Dalton, W. S., Jove, R. (1999). Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 10(1):105-115.
29. Cerny, T., Borisch, B., Introna, M., Johnson, P., Rose, A. L. (2002). Mechanism of action of rituximab. Anticancer Drugs 13 (Suppl 2):S3-10.
30. Chang, C. J., Tai, K. F., Roffler, S., Hwang, L. H. (2004). The immunization site of cytokine-secreting tumor cell vaccines influences the trafficking of tumor-specific T lymphocytes and antitumor efficacy against regional tumors. J. Immunol. 173(10):6025-6032.
31. Chen, L. K., Tourvieille, B., Burns, G. F., Bach, F. H., Mathieu-Mahul, D., Sasportes, M., Bensussan, A. (1986). Interferon: a cytotoxic T lymphocyte differentiation signal. Eur. J. Immunol. 16(7):767-770.
32. Cheng, F., Wang, H. W., Cuenca, A., Huang, M., Ghansah, T., Brayer, J., Kerr, W. G., Takeda, K., Akira, S., Schoenberger, S. P., Yu, H., Jove, R., Sotomayor, E. M. (2003). A critical role for Stat3 signaling in immune tolerance. Immunity 19(3):425-436.
33. Chin, Y. E., Kitagawa, M., Su, W. C., You, Z. H., Iwamoto, Y., Fu, X. Y. (1996). Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272(5262):719-722.
34. Cohen, C. J., Zheng, Z., Bray, R., Zhao, Y., Sherman, L. A., Rosenberg, S. A., Morgan, R. A. (2005). Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR. J. Immunol. 175(9):5799-5808.
35. Collart, M. A., Belin, D., Vassalli, J. D., de Kossodo, S., Vassalli, P. (1986). Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors. J. Exp. Med. 164(6):2113-2118.
36. Couch, M., Saunders, J. K., O'Malley, B. W., Jr., Pardoll, D., Jaffee, E. (2003). Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope 113(3):552-556.
37. Coukos, G., Conejo-Garcia, J. R., Roden, R. B., Wu, T. C. (2005). Immunotherapy for gynaecological malignancies. Expert Opin. Biol. Ther. 5(9):1193-1210.
38. Coussens, L. M., Tinkle, C. L., Hanahan, D., Werb, Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103(3):481-490.
39. Coussens, L. M., Werb, Z. (2002). Inflammation and cancer. Nature 420(6917):860-867.
40. Cozar, J. M., Canton, J., Tallada, M., Concha, A., Cabrera, T., Garrido, F., Ruiz-Cabello Osuna, F. (2005). Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. Cancer Immunol. Immunother. 54(9):858-866.
41. Curiel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., Zhu, Y., Wei, S., Kryczek, I., Daniel, B., Gordon, A., Myers, L., Lackner, A., Disis, M. L., Knutson, K. L., Chen, L., Zou, W. (2004). Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat. Med. 10(9):942-949.
42. Daniel, D., Chiu, C., Giraudo, E., Inoue, M., Mizzen, L. A., Chu, N. R., Hanahan, D. (2005). CD4+ T cell-mediated antigen-specific immunotherapy in a mouse model of cervical cancer. Cancer Res. 65(5):2018-2025.
43. Daniel, D., Meyer-Morse, N., Bergsland, E. K., Dehne, K., Coussens, L. M., Hanahan, D. (2003). Immune enhancement of skin carcinogenesis by CD4+ T cells. J. Exp. Med. 197(8):1017-1028.
44. Darnell, J. E., Jr. (1997). STATs and gene regulation. Science 277(5332):1630-1635.
45. Davis, T. A., Grillo-Lopez, A. J., White, C. A., McLaughlin, P., Czuczman, M. S., Link, B. K., Maloney, D. G., Weaver, R. L., Rosenberg, J., Levy, R. (2000). Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J. Clin. Oncol. 18(17):3135-3143.
46. Davis, T. A., Maloney, D. G., Czerwinski, D. K., Liles, T. M., Levy, R. (1998). Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone. Blood 92(4):1184-1190.
47. Dilulio, N. A., Engeman, T., Armstrong, D., Tannenbaum, C., Hamilton, T. A., Fairchild, R. L. (1999). Groalpha-mediated recruitment of neutrophils is required for elicitation of contact hypersensitivity. Eur. J. Immunol. 29(11):3485-3495.
48. Djeu, J. Y., Stocks, N., Zoon, K., Stanton, G. J., Timonen, T., Herberman, R. B. (1982). Positive self regulation of cytotoxicity in human natural killer cells by production of interferon upon exposure to influenza and herpes viruses. J. Exp. Med. 156(4):1222-1234.
49. Dobrzanski, M. J., Reome, J. B., Dutton, R. W. (2001). Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin. Immunol. 98(1):70-84.
50. Dominiecki, M. E., Beatty, G. L., Pan, Z. K., Neeson, P., Paterson, Y. (2005). Tumor sensitivity to IFN-gamma is required for successful antigen-specific immunotherapy of a transplantable mouse tumor model for HPV-transformed tumors. Cancer Immunol. Immunother. 54(5):477-488.
51. Dunn, G. P., Old, L. J., Schreiber, R. D. (2004a). The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21(2):137-148.
52. Dunn, G. P., Old, L. J., Schreiber, R. D. (2004b). The three Es of cancer immuno editing. Annu. Rev. Immunol. 22:329-360.
53. Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., Neri, D. (2005). Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer 116(2):304-313.
54. Engeman, T., Gorbachev, A. V., Kish, D. D., Fairchild, R. L. (2004). The intensity of neutrophil infiltration controls the number of antigen-primed CD8 T cells recruited into cutaneous antigen challenge sites. J. Leukoc. Biol. 76(5):941-949.
55. Epling-Burnette, P. K., Liu, J. H., Catlett-Falcone, R., Turkson, J., Oshiro, M., Kothapalli, R., Li, Y., Wang, J. M., Yang-Yen, H. F., Karras, J., Jove, R., Loughran, T. P., Jr. (2001). Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression. J. Clin. Invest. 107(3):351-362.
56. Farber, J. M. (1997). Mig and IP-10: CXC chemokines that target lymphocytes. J. Leukoc. Biol. 61(3):246-257.
57. Farrar, M. A., Schreiber, R. D. (1993). The molecular cell biology of interferon-gamma and its receptor. Annu. Rev. Immunol. 11:571-611.
58. Feldman, A. L., Alexander, H. R., Hewitt, S. M., Lorang, D., Thiruvathukal, C. E., Turner, E. M., Libutti, S. K. (2001). Effect of retroviral endostatin gene transfer on subcutaneous and intraperitoneal growth of murine tumors. J. Natl. Cancer Inst. 93(13):1014-1020.
59. Gattinoni, L., Finkelstein, S. E., Klebanoff, C. A., Antony, P. A., Palmer, D. C., Spiess, P. J., Hwang, L. N., Yu, Z., Wrzesinski, C., Heimann, D. M., Surh, C. D., Rosenberg, S. A., Restifo, N. P. (2005). Removal of homeostatic cytokine sinks by lympho depletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202(7):907-912.
60. Gee, M. S., Koch, C. J., Evans, S. M., Jenkins, W. T., Pletcher, C. H., Jr., Moore, J. S., Koblish, H. K., Lee, J., Lord, E. M., Trinchieri, G., Lee, W. M. (1999). Hypoxia-mediated apoptosis from angiogenesis inhibition underlies tumor control by recombinant interleukin 12. Cancer Res. 59(19):4882-4889.
61. Gee, M. S., Procopio, W. N., Makonnen, S., Feldman, M. D., Yeilding, N. M., Lee, W. M. (2003). Tumor vessel development and maturation impose limits on the effectiveness of anti-vascular therapy. Am. J. Pathol. 162(1):183-193.
62. Golgher, D., Jones, E., Powrie, F., Elliott, T., Gallimore, A. (2002). Depletion of CD25+ regulatory cells uncovers immune responses to shared murine tumor rejection antigens. Eur. J. Immunol. 32(11):3267-3275.
63. Gough, M., Crittenden, M., Thanarajasingam, U., Sanchez-Perez, L., Thompson, J., Jevremovic, D., Vile, R. (2005). Gene therapy to manipulate effector T cell trafficking to tumors for immunotherapy. J. Immunol. 174(9):5766-5773.
64. Greenlund, A. C., Morales, M. O., Viviano, B. L., Yan, H., Krolewski, J., Schreiber, R. D. (1995). Stat recruitment by tyrosine-phosphorylated cytokine receptors: an ordered reversible affinity-driven process. Immunity 2(6):677-687.
65. Gunn, G. R., Zubair, A., Peters, C., Pan, Z. K., Wu, T. C., Paterson, Y. (2001). Two Listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J. Immunol. 167(11):6471-6479.
66. Guy, C. T., Cardiff, R. D., Muller, W. J. (1992a). Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol. Cell. Biol. 12(3):954-961.
67. Guy, C. T., Webster, M. A., Schaller, M., Parsons, T. J., Cardiff, R. D., Muller, W. J. (1992b). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc. Natl. Acad. Sci. USA 89(22):10578-10582.
68. Hamano, Y., Zeisberg, M., Sugimoto, H., Lively, J. C., Maeshima, Y., Yang, C., Hynes, R. O., Werb, Z., Sudhakar, A., Kalluri, R. (2003). Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell 3(6):589-601.
69. Hanahan, D., Folkman, J. (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86(3):353-364.
70. Hemmann, U., Gerhartz, C., Heesel, B., Sasse, J., Kurapkat, G., Grotzinger, J., Wollmer, A., Zhong, Z., Darnell, J. E., Jr., Graeve, L., Heinrich, P. C., Horn, F. (1996). Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130. II. Src homology SH2 domains define the specificity of stat factor activation. J. Biol. Chem. 271(22):12999-13007.
71. Hinrichs, C. S., Palmer, D. C., Rosenberg, S. A., Restifo, N. P. (2005). Glucocorticoids do not inhibit antitumor activity of activated CD8+ T cells. J. Immunother. 28(6):517-524.
72. Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., Wiegand, S. J. (1999). Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 284(5422):1994-1998.
73. Homey, B., Alenius, H., Muller, A., Soto, H., Bowman, E. P., Yuan, W., McEvoy, L., Lauerma, A. I., Assmann, T., Bunemann, E., Lehto, M., Wolff, H., Yen, D., Marxhausen, H., To, W., Sedgwick, J., Ruzicka, T., Lehmann, P., Zlotnik, A. (2002). CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8(2):157-165.
74. Horvath, C. M., Wen, Z., Darnell, J. E., Jr. (1995). A STAT protein domain that determines DNA sequence recognition suggests a novel DNA-binding domain. Genes Dev. 9(8):984-994.
75. Hsu, F. J., Caspar, C. B., Czerwinski, D., Kwak, L. W., Liles, T. M., Syrengelas, A., Taidi-Laskowski, B., Levy, R. (1997). Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma-long-term results of a clinical trial. Blood 89(9):3129-3135.
76. Huang, J., Khong, H. T., Dudley, M. E., El-Gamil, M., Li, Y. F., Rosenberg, S. A., Robbins, P. F. (2005). Survival, persistence, and progressive differentiation of adoptively transferred tumor-reactive T cells associated with tumor regression. J. Immunother. 28(3):258-267.
77. Hussain, S. F., Paterson, Y. (2004). CD4 + CD25+regulatory T cells that secrete TGF-beta and IL-10 are preferentially induced by a vaccine vector. J. Immunother. 27(5):339-346.
78. Hussein, M. R. (2005). Tumour-infiltrating lymphocytes and melanoma tumorigenesis: an insight. Br. J. Dermatol. 153(1):18-21.
79. Iellem, A., Mariani, M., Lang, R., Recalde, H., Panina-Bordignon, P., Sinigaglia, F., D'Ambrosio, D. (2001). Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J. Exp. Med. 194(6):847-853.
80. Ishida, Y., Kondo, T., Takayasu, T., Iwakura, Y., Mukaida, N. (2004). The essential involvement of cross-talk between IFN-gamma and TGF-beta in the skin wound-healing process. J. Immunol. 172(3):1848-1855.
81. Itoh, T., Storkus, W. J., Gorelik, E., Lotze, M. T. (1994). Partial purification of murine tumor-associated peptide epitopes common to histologically distinct tumors, melanoma and sarcoma, that are presented by H-2Kb molecules and recognized by CD8+ tumor-infiltrating lymphocytes. J. Immunol. 153(3):1202-1215.
82. Janeway, C. A., Travers, P., Walport, M., Shlomchik, M. J. (2005). Adaptive Immunity to infection. In: Janeway, C. A., Travers, P., Walport, M., Shlomchik, M. J. Immunobiology. Garland Science Publishing, pp. 435-436.
83. Jia, Z. C., Zou, L. Y., Ni, B., Wan, Y., Zhou, W., Lv, Y. B., Geng, M., Wu, Y. Z. (2005). Effective induction of antitumor immunity by immunization with plasmid DNA encoding TRP-2 plus neutralization of TGF-beta. Cancer Immunol. Immunother. 54(5):446-452.
84. Joncker, N. T., Marloie, M. A., Chernysheva, A., Lonchay, C., Cuff, S., Klijanienko, J., Sigal-Zafrani, B., Vincent-Salomon, A., Sastre, X., Lantz, O. (2005). Antigen-independent accumulation of activated effector/memory T lymphocytes into human and murine tumors. Int. J. Cancer. 118(5):1205-1214.
85. Kageshita, T., Ishihara, T., Campoli, M., Ferrone, S. (2005). Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions. Tissue Antigens 65(5):419-428.
86. Kalish, R. S., Johnson, K. L. (1990). Enrichment and function of urushiol (poison ivy)-specific T lymphocytes in lesions of allergic contact dermatitis to urushiol. J. Immunol. 145(11):3706-3713.
87. Kaminska, B., Wesolowska, A., Danilkiewicz, M. (2005). TGF beta signalling and its role in tumour pathogenesis. Acta Biochim. Pol. 52(2):329-337.
88. Kaminski, M. S., Kitamura, K., Maloney, D. G., Campbell, M. J., Levy, R. (1986). Importance of antibody isotype in monoclonal anti-idiotype therapy of a murine B cell lymphoma. A study of hybridoma class switch variants. J. Immunol. 136(3):1123-1130.
89. Kaminski, M. S., Kitamura, K., Maloney, D. G., Levy, R. (1987). Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein. J. Immunol. 138(4):1289-1296.
90. Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., Schreiber, R. D. (1998). Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 95(13):7556-61.
91. Khong, H. T., Wang, Q. J., Rosenberg, S. A. (2004). Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression. J. Immunother. 27(3):184-190.
92. Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., Ferrara, N. (1993). Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362(6423):841-844.
93. Kunkel, E. J., Butcher, E. C. (2002). Chemokines and the tissue-specific migration of lymphocytes. Immunity 16(1):1-4.
94. Kunz, M., Toksoy, A., Goebeler, M., Engelhardt, E., Brocker, E., Gillitzer, R. (1999). Strong expression of the lymphoattractant C-X-C chemokine Mig is associated with heavy infiltration of T cells in human malignant melanoma. J. Pathol. 189(4):552-558.
95. Kwak, L. W., Young, H. A., Pennington, R. W., Weeks, S. D. (1996). Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93(20):10972-10977.
96. Lally, K. M., Mocellin, S., Ohnmacht, G. A., Nielsen, M. B., Bettinotti, M., Panelli, M. C., Monsurro, V., Marincola, F. M. (2001). Unmasking cryptic epitopes after loss of immunodominant tumor antigen expression through epitope spreading. Int. J. Cancer 93(6):841-847.
97. Lamikanra, A., Pan, Z. K., Isaacs, S. N., Wu, T. C., Paterson, Y. (2001). Regression of established human papillomavirus type 16 (HPV-16) immortalized tumors in vivo by vaccinia viruses expressing different forms of HPV-16 E7 correlates with enhanced CD8(+) T-cell responses that home to the tumor site. J. Virol. 75(20):9654-9664.
98. Levy, D. E., Darnell, J. E., Jr. (2002). Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell. Biol. 3(9):651-662.
99. Li, Y., Wang, M. N., Li, H., King, K. D., Bassi, R., Sun, H., Santiago, A., Hooper, A. T., Bohlen, P., Hicklin, D. J. (2002). Active immunization against the vascular endothelial growth factor receptor flk1 inhibits tumor angiogenesis and metastasis. J. Exp. Med. 195(12):1575-1584.
100. Lin, K. Y., Guarnieri, F. G., Staveley-O'Carroll, K. F., Levitsky, H. I., August, J. T., Pardoll, D. M., Wu, T. C. (1996). Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res. 56(1):21-26.
101. Liu, K., Caldwell, S. A., Abrams, S. I. (2005). Immune selection and emergence of aggressive tumor variants as negative consequences of Fas-mediated cytotoxicity and altered IFN-gamma-regulated gene expression. Cancer Res. 65(10):4376-4388.
102. Liyanage, U. K., Moore, T. T., Joo, H. G., Tanaka, Y., Herrmann, V., Doherty, G., Drebin, J. A., Strasberg, S. M., Eberlein, T. J., Goedegebuure, P. S., Linehan, D. C. (2002). Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J. Immunol. 169(5):2756-2761.
103. Luboshits, G., Shina, S., Kaplan, O., Engelberg, S., Nass, D., Lifshitz-Mercer, B., Chaitchik, S., Keydar, I., Ben-Baruch, A. (1999). Elevated expression of the CC chemokine regulated on activation, normal T cell expressed and secreted (RANTES) in advanced breast carcinoma. Cancer Res. 59(18):4681-4687.
104. Lugade, A. A., Moran, J. P., Gerber, S. A., Rose, R. C., Frelinger, J. G., Lord, E. M. (2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J. Immunol. 174(12):7516-7523.
105. Maloney, D. G. (2001). Mechanism of action of rituximab. Anticancer Drugs 12 Suppl 2:S1-4.
106. Maraskovsky, E., Chen, W. F., Shortman, K. (1989). IL-2 and IFN-gamma are two necessary lymphokines in the development of cytolytic T cells. J. Immunol. 143(4):1210-1214.
107. Maric, M., Liu, Y. (1999). Strong cytotoxic T lymphocyte responses to a macrophage inflammatory protein 1alpha-expressing tumor: linkage between inflammation and specific immunity. Cancer Res. 59(21):5549-5553.
108. Meeker, T., Lowder, J., Cleary, M. L., Stewart, S., Warnke, R., Sklar, J., Levy, R. (1985). Emergence of idiotype variants during treatment of B-cell lymphoma with anti-idiotype antibodies. N. Engl. J. Med. 312(26):1658-1665.
109. Meissner, M., Reichert, T. E., Kunkel, M., Gooding, W., Whiteside, T. L., Ferrone, S., Seliger, B. (2005). Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin. Cancer Res. 11(7):2552-2560.
110. Meziane el, K., Bhattacharyya, T., Armstrong, A. C., Qian, C., Hawkins, R. E., Stern, P. L., Dermime, S. (2004). Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma. Int J Cancer 111(6):910-920.
111. Mule, J. J., Custer, M., Averbook, B., Yang, J. C., Weber, J. S., Goeddel, D. V., Rosenberg, S. A., Schall, T. J. (1996). RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations. Hum. Gene Ther. 7(13):1545-1553.
112. Nair, S., Boczkowski, D., Moeller, B., Dewhirst, M., Vieweg, J., Gilboa, E. (2003). Synergy between tumor immunotherapy and antiangiogenic therapy. Blood 102(3):964-971.
113. Nathan, C. F., Hibbs, J. B., Jr. (1991). Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr. Opin. Immunol. 3(1):65-70.
114. Neelapu, S. S., Gause, B. L., Nikcevich, D. A., Schuster, S. J., Winter, J., Gockerman, J. P., Loughran, T., Jr., Takeshita, K., Inghirami, G., McGaughey, D., Watson, T. M., Snow, S., Kubovic, P., Ferraro, M., Jones, E., Jaffe, E. S., Schwartzentruber, D. J., Danforth, D., Sherry, R., Kass, E., Van Waes, C., Reynolds, C. W., Kwak, L. J. (2005). Phase III randomized trial of patient-specific vaccination for previously untreated patients with follicular lymphoma in first complete remission: protocol summary and interim report. Clin. Lymphoma 6(1):61-64.
115. Negus, R. P., Stamp, G. W., Hadley, J., Balkwill, F. R. (1997). Quantitative assessment of the leukocyte infiltrate in ovarian cancer and its relationship to the expression of C-C chemokines. Am. J. Pathol. 150(5):1723-1734.
116. Niethammer, A. G., Xiang, R., Becker, J. C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B. P., Reisfeld, R. A. (2002). A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat. Med. 8(12):1369-1375.
117. Niwa, Y., Akamatsu, H., Niwa, H., Sumi, H., Ozaki, Y., Abe, A. (2001). Correlation of tissue and plasma RANTES levels with disease course in patients with breast or cervical cancer. Clin. Cancer Res. 7(2):285-289.
118. Onizuka, S., Tawara, I., Shimizu, J., Sakaguchi, S., Fujita, T., Nakayama, E. (1999). Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody. Cancer Res. 59(13):3128-3133.
119. Palmer, D. C., Balasubramaniam, S., Hanada, K., Wrzesinski, C., Yu, Z., Farid, S., Theoret, M. R., Hwang, L. N., Klebanoff, C. A., Gattinoni, L., Goldstein, A. L., Yang, J. C., Restifo, N. P. (2004). Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction. J. Immunol. 173(12):7209-7216.
120. Pamer, E. G. (2004). Immune responses to Listeria monocytogenes. Nat. Rev. Immunol. 4(10):812-823.
121. Pan, Z. K., Weiskirch, L. M., Paterson, Y. (1999). Regression of established B16F10 melanoma with a recombinant Listeria monocytogenes vaccine. Cancer Res. 59(20):5264-5269.
122. Paterson, Y., Maciag, P. C. (2005). Listeria-based vaccines for cancer treatment. Curr. Opin. Mol. Ther. 7(5):454-460.
123. Pertl, U., Luster, A. D., Varki, N. M., Homann, D., Gaedicke, G., Reisfeld, R. A., Lode, H. N. (2001). IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy. J. Immunol. 166(11):6944-6951.
124. Piccirillo, C. A., Shevach, E. M. (2004). Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16(2):81-88.
125. Piguet, P. F., Grau, G. E., Hauser, C., Vassalli, P. (1991). Tumor necrosis factor is a critical mediator in hapten induced irritant and contact hypersensitivity reactions. J. Exp. Med. 173(3):673-679.
126. Pollard, J. W. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat. Rev. Cancer 4(1):71-78.
127. Porter, D. L., June, C. H. (2005). T-cell reconstitution and expansion after hematopoietic stem cell transplantation: 'T' it up! Bone Marrow Transplant 35(10):935-942.
128. Qing, Y., Stark, G. R. (2004). Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J. Biol. Chem. 279(40):41679-41685.
129. Rapoport, A. P., Stadtmauer, E. A., Aqui, N., Badros, A., Cotte, J., Chrisley, L., Veloso, E., Zheng, Z., Westphal, S., Mair, R., Chi, N., Ratterree, B., Pochran, M. F., Natt, S., Hinkle, J., Sickles, C., Sohal, A., Ruehle, K., Lynch, C., Zhang, L., Porter, D. L., Luger, S., Guo, C., Fang, H. B., Blackwelder, W., Hankey, K., Mann, D., Edelman, R., Frasch, C., Levine, B. L., Cross, A., June, C. H. (2005). Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat. Med. 11(11):1230-1237.
130. Reilly, R. T., Machiels, J. P., Emens, L. A., Jaffee, E. M. (2002). Cytokine gene-modified cell-based cancer vaccines. Meth. Mol. Med. 69:233-257.
131. Reiss, Y., Proudfoot, A. E., Power, C. A., Campbell, J. J., Butcher, E. C. (2001). CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194(10):1541-1547.
132. Ribas, A., Glaspy, J. A., Lee, Y., Dissette, V. B., Seja, E., Vu, H. T., Tchekmedyian, N. S., Oseguera, D., Comin-Anduix, B., Wargo, J. A., Amarnani, S. N., McBride, W. H., Economou, J. S., Butterfield, L. H. (2004). Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J. Immunother. 27(5):354-367.
133. Rosa, F. M., Cochet, M. M., Fellous, M. (1986). Interferon and major histocompatibility complex genes: a model to analyse eukaryotic gene regulation? Interferon 7:47-87.
134. Rovero, S., Amici, A., Carlo, E. D., Bei, R., Nanni, P., Quaglino, E., Porcedda, P., Boggio, K., Smorlesi, A., Lollini, P. L., Landuzzi, L., Colombo, M. P., Giovarelli, M., Musiani, P., Forni, G. (2000). DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J. Immunol. 165(9):5133-5142.
135. Ruffini, P. A., Biragyn, A., Coscia, M., Harvey, L. K., Cha, S. C., Bogen, B., Kwak, L. W. (2004). Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J. Leukoc. Biol. 76(1):77-85.
136. Sakaguchi, S. (2005). Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-self. Nat. Immunol. 6(4):345-352.
137. Saleh, F., Renno, W., Klepacek, I., Ibrahim, G., Dashti, H., Asfar, S., Behbehani, A., Al-Sayer, H., Dashti, A., Kerry, C. (2005). Direct evidence on the immune-mediated spontaneous regression of human cancer: an incentive for pharmaceutical companies to develop a novel anti-cancer vaccine. Curr. Pharm. Des. 11(27):3531-3543.
138. Sallusto, F., Lenig, D., Forster, R., Lipp, M., Lanzavecchia, A. (1999). Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401(6754):708-712.
139. Sallusto, F., Lenig, D., Mackay, C. R., Lanzavecchia, A. (1998). Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J. Exp. Med. 187(6):875-883.
140. Sallusto, F., Mackay, C. R. (2004). Chemoattractants and their receptors in homeostasis and inflammation. Curr. Opin. Immunol. 16(6):724-731.
141. Sallusto, F., Mackay, C. R., Lanzavecchia, A. (2000). The role of chemokine receptors in primary, effector, and memory immune responses. Annu. Rev. Immunol. 18:593-620.
142. Sanchez-Perez, L., Kottke, T., Diaz, R. M., Ahmed, A., Thompson, J., Chong, H., Melcher, A., Holmen, S., Daniels, G., Vile, R. G. (2005). Potent selection of antigen loss variants of B16 melanoma following inflammatory killing of melanocytes in vivo. Cancer Res. 65(5):2009-2017.
143. Sano, S., Itami, S., Takeda, K., Tarutani, M., Yamaguchi, Y., Miura, H., Yoshikawa, K., Akira, S., Takeda, J. (1999). Keratinocyte-specific ablation of Stat3 exhibits impaired skin remodeling, but does not affect skin morphogenesis. Embo. J. 18(17):4657-4668.
144. Sauer, M. G., Ericson, M. E., Weigel, B. J., Herron, M. J., Panoskaltsis-Mortari, A., Kren, B. T., Levine, B. L., Serody, J. S., June, C.
145. Scheffer, S. R., Nave, H., Korangy, F., Schlote, K., Pabst, R., Jaffee, E. M., Manns, M. P., Greten, T. F. (2003). Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer. 103(2):205-211.
146. Schindler, C., Darnell, J. E., Jr. (1995). Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu. Rev. Biochem. 64:621-651.
147. Schreiber, R. D., Farrar, M. A. (1993). The biology and biochemistry of interferon-gamma and its receptor. Gastroenterol Jpn 28 (Suppl. 4):88-94; discussion 95-96.
148. Seidel, H. M., Milocco, L. H., Lamb, P., Darnell, J. E., Jr., Stein, R. B., Rosen, J. (1995). Spacing of palindromic half sites as a determinant of selective STAT (signal transducers and activators of transcription) DNA binding and transcriptional activity. Proc. Natl. Acad. Sci. USA 92(7):3041-3045.
149. Serafini, P., Borrello, I., Bronte, V. (2005). Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol. 16(1):53-65.
150. Serafini, P., De Santo, C., Marigo, I., Cingarlini, S., Dolcetti, L., Gallina, G., Zanovello, P., Bronte, V. (2004). Derangement of immune responses by myeloid suppressor cells. Cancer Immunol. Immunother. 53(2):64-72.
151. Sharma, S., Stolina, M., Zhu, L., Lin, Y., Batra, R., Huang, M., Strieter, R., Dubinett, S. M. (2001). Secondary lymphoid organ chemokine reduces pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma. Cancer Res 61(17):6406-12.
152. Shi, W., Teschendorf, C., Muzyczka, N., Siemann, D. W. (2002). Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo. Cancer Gene Ther. 9(6):513-521.
153. Shimizu, J., Yamazaki, S., Sakaguchi, S. (1999). Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10):5211-5218.
154. Singh, R., Dominiecki, M. E., Jaffee, E. M., Paterson, Y. (2005). Fusion to listeriolysin O and delivery by Listeria monocytogenes enhances the immunogenicity of HER-2/neu and reveals subdominant epitopes in the FVB/N mouse. J. Immunol. 175(6):3663-3673.
155. Sinibaldi, D., Wharton, W., Turkson, J., Bowman, T., Pledger, W. J., Jove, R. (2000). Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling. Oncogene 19(48):5419-5427.
156. Song, W., Levy, R. (2005). Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. Cancer Res. 65(13):5958-5964.
157. Spiess, P. J., Yang, J. C., Rosenberg, S. A. (1987). In vivo antitumor activity of tumor-infiltrating lymphocytes expanded in recombinant interleukin-2. J. Natl. Cancer Inst. 79(5):1067-1075.
158. Spiotto, M. T., Fu, Y. X., Schreiber, H. (2003a). Tumor immunity meets autoimmunity: antigen levels and dendritic cell maturation. Curr. Opin. Immunol. 15(6):725-730.
159. Spiotto, M. T., Reth, M. A., Schreiber, H. (2003b). Genetic changes occurring in established tumors rapidly stimulate new antibody responses. Proc. Natl. Acad. Sci. USA 100(9):5425-5430.
160. Spiotto, M. T., Rowley, D. A., Schreiber, H. (2004). Bystander elimination of antigen loss variants in established tumors. Nat. Med. 10(3):294-298.
161. Spiotto, M. T., Schreiber, H. (2005). Rapid destruction of the tumor microenvironment by CTLs recognizing cancer-specific antigens cross-presented by stromal cells. Cancer Immun. 5:8.
162. Spiotto, M. T., Yu, P., Rowley, D. A., Nishimura, M. I., Meredith, S. C., Gajewski, T. F., Fu, Y. X., Schreiber, H. (2002). Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity 17(6):737-747.
163. Stevens, T., Rosenberg, R., Aird, W., Quertermous, T., Johnson, F. L., Garcia, J. G., Hebbel, R. P., Tuder, R. M., Garfinkel, S. (2001). NHLBI workshop report: endothelial cell phenotypes in heart, lung, and blood diseases. Am. J. Physiol. Cell. Physiol. 281(5):C1422-1433.
164. Sun, H., Kundu, N., Dorsey, R., Jackson, M. J., Fulton, A. M. (2001). Expression of the chemokines IP-10 and Mig in IL-10 transduced tumors. J. Immunother. 24(2):138-143.
165. Sutmuller, R. P., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N., Wildenberg, M. E., Allison, J. P., Toes, R. E., Offringa, R., Melief, C. J. (2001). Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194(6):823-832.
166. Tang, H. L., Cyster, J. G. (1999). Chemokine up-regulation and activated T cell attraction by maturing dendritic cells. Science 284(5415):819-822.
167. Tang, K. F., Tan, S. Y., Chan, S. H., Chong, S. M., Loh, K. S., Tan, L. K., Hu, H. (2001). A distinct expression of CC chemokines by macrophages in nasopharyngeal carcinoma: implication for the intense tumor infiltration by T lymphocytes and macrophages. Hum. Pathol. 32(1):42-49.
168. Timmerman, J. M., Caspar, C. B., Lambert, S. L., Syrengelas, A. D., Levy, R. (2001). Idiotype-encoding recombinant adenoviruses provide protective immunity against murine B-cell lymphomas. Blood 97(5):1370-1377.
169. Timmerman, J. M., Czerwinski, D. K., Davis, T. A., Hsu, F. J., Benike, C., Hao, Z. M., Taidi, B., Rajapaksa, R., Caspar, C. B., Okada, C. Y., van Beckhoven, A., Liles, T. M., Engleman, E. G., Levy, R. (2002). Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99(5):1517-1526.
170. Trinchieri, G. (1998). Immunobiology of interleukin-12. Immunol Res 17(1-2):269-278.
171. Troyanovsky B., Levchenko T., Mansson G., Matvijenko O., Holmgren L. (2001) Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J. Cell. Biol. 152(6):1247-1254.
172. Vitale, M., Pelusi, G., Taroni, B., Gobbi, G., Micheloni, C., Rezzani, R., Donato, F., Wang, X., Ferrone, S. (2005). HLA class I antigen down-regulation in primary ovary carcinoma lesions: association with disease stage. Clin. Cancer Res. 11(1):67-72.
173. Wada, S., Tsunoda, T., Baba, T., Primus, F. J., Kuwano, H., Shibuya, M., Tahara, H. (2005). Rationale for antiangiogenic cancer therapy with vaccination using epitope peptides derived from human vascular endothelial growth factor receptor 2. Cancer Res. 65(11):4939-4946.
174. Wang, T., Niu, G., Kortylewski, M., Burdelya, L., Shain, K., Zhang, S., Bhattacharya, R., Gabrilovich, D., Heller, R., Coppola, D., Dalton, W., Jove, R., Pardoll, D., Yu, H. (2004). Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 10(1):48-54.
175. Wang, Z., Margulies, L., Hicklin, D. J., Ferrone, S. (1996). Molecular and functional phenotypes of melanoma cells with abnormalities in HLA class I antigen expression. Tissue Antigens 47(5):382-390.
176. Wei, S., Kryczek, I., Zou, L., Daniel, B., Cheng, P., Mottram, P., Curiel, T., Lange, A., Zou, W. (2005). Plasmacytoid dendritic cells induce CD8+ regulatory T cells in human ovarian carcinoma. Cancer Res. 65(12):5020-5026.
177. Whiteside, T. L., Stanson, J., Shurin, M. R., Ferrone, S. (2004). Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells. J. Immunol. 173(3):1526-1534.
178. Wiederkehr-Adam, M., Ernst, P., Muller, K., Bieck, E., Gombert, F. O., Ottl, J., Graff, P., Grossmuller, F., Heim, M. H. (2003). Characterization of phosphopeptide motifs specific for the Src homology 2 domains of signal transducer and activator of transcription 1 (STAT1) and STAT3. J. Biol. Chem. 278(18):16117-16128.
179. Woo, E. Y., Chu, C. S., Goletz, T. J., Schlienger, K., Yeh, H., Coukos, G., Rubin, S. C., Kaiser, L. R., June, C. H. (2001). Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 61(12):4766-4772.
180. Wu, M., Fang, H., Hwang, S. T. (2001a). Cutting edge: CCR4 mediates antigen-primed T cell binding to activated dendritic cells. J. Immunol. 167(9):4791-4795.
181. Wu, R. S., Kobie, J. J., Besselsen, D. G., Fong, T. C., Mack, V. D., McEarchern, J. A., Akporiaye, E. T. (2001b). Comparative analysis of IFN-gamma B7.1 and antisense TGF-beta gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol. Immunother. 50(5):229-240.
182. Xu, H., DiIulio, N. A., Fairchild, R. L. (1996). T cell populations primed by hapten sensitization in contact sensitivity are distinguished by polarized patterns of cytokine production: interferon gamma-producing (Tc1) effector CD8+ T cells and interleukin (Il) 4/Il-10-producing (Th2) negative regulatory CD4+ T cells. J. Exp. Med. 183(3):1001-1012.
183. Yamshchikov, G. V., Mullins, D. W., Chang, C. C., Ogino, T., Thompson, L., Presley, J., Galavotti, H., Aquila, W., Deacon, D., Ross, W., Patterson, J. W., Engelhard, V. H., Ferrone, S., Slingluff, C. L., Jr. (2005). Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. J. Immunol. 174(11):6863-6871.
184. Yang, Y., Huang, C. T., Huang, X., Pardoll, D. M. (2004). Persistent Toll-like receptor signals are required for reversal of regulatory T cell-mediated CD8 tolerance. Nat. Immunol. 5(5):508-515.
185. Yee, C., Thompson, J. A., Byrd, D., Riddell, S. R., Roche, P., Celis, E., Greenberg, P. D. (2002). Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA 99(25):16168-16173.
186. Yoong, K. F., Afford, S. C., Jones, R., Aujla, P., Qin, S., Price, K., Hubscher, S. G., Adams, D. H. (1999). Expression and function of CXC and CC chemokines in human malignant liver tumors: a role for human monokine induced by gamma-interferon in lymphocyte recruitment to hepatocellular carcinoma. Hepatology 30(1):100-111.
187. Yu, P., Spiotto, M. T., Lee, Y., Schreiber, H., Fu, Y. X. (2003). Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells. J. Exp. Med. 197(8):985-995.
188. Zhang, Q., Jang, T. L., Yang, X., Park, I., Meyer, R. E., Kundu, S., Pins, M., Javonovic, B., Kuzel, T., Kim, S. J., Van Parijs, L., Smith, N., Wong, L., Greenberg, N. M., Guo, Y., Lee, C. (2005a). Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8(+) T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells. Prostate. 66(3):235-247.
189. Zhang, Q., Yang, X., Pins, M., Javonovic, B., Kuzel, T., Kim, S. J., Parijs, L. V., Greenberg, N. M., Liu, V., Guo, Y., Lee, C. (2005b). Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer. Cancer Res. 65(5):1761-1769.
190. Zhang, T., Somasundaram, R., Berencsi, K., Caputo, L., Rani, P., Guerry, D., Furth, E., Rollins, B. J., Putt, M., Gimotty, P., Swoboda, R., Herlyn, M., Herlyn, D. (2005c). CXC chemokine ligand 12 (stromal cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma cells in organotypic culture. J. Immunol. 174(9):5856-5863.
191. Zhou, G., Lu, Z., McCadden, J. D., Levitsky, H. I., Marson, A. L. (2004). Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J. Exp. Med. 200(12):1581-1592.
192. Zhou, J., Dudley, M. E., Rosenberg, S. A., Robbins, P. F. (2005a). Persistence of multiple tumor-specific T-cell clones is associated with complete tumor regression in a melanoma patient receiving adoptive cell transfer therapy. J. Immunother. 28(1):53-62.
193. Zhou, H., Luo. Y., Mizutani, M., Mizutani, N., Reisfeld, R. A., Xiang, R. (2005b) T cell-mediated suppression of angiogenesis results in tumor protective immunity. Blood 106(6):2026-2032.